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Abstract
Over the past 30 years, benzimidazoles have increasingly been used to treat cystic echinococcosis (CE). The efficacy of
benzimidazoles, however, remains unclear. We systematically searched MEDLINE, EMBASE, SIGLE, and CCTR to identify
studies on benzimidazole treatment outcome. A large heterogeneity of methods in 23 reports precluded a meta-analysis
of published results. Specialist centres were contacted to provide individual patient data. We conducted survival analyses
for cyst response defined as inactive (CE4 or CE5 by the ultrasound-based World Health Organisation [WHO] classification
scheme) or as disappeared. We collected data from 711 treated patients with 1,308 cysts from six centres (five countries).
Analysis was restricted to 1,159 liver and peritoneal cysts. Overall, 1–2 y after initiation of benzimidazole treatment
50%–75% of active C1 cysts were classified as inactive/disappeared compared to 30%–55% of CE2 and CE3 cysts. Further
in analyzing the rate of inactivation/disappearance with regard to cyst size, 50%–60% of cysts ,6 cm responded to
treatment after 1–2 y compared to 25%–50% of cysts .6 cm. However, 25% of cysts reverted to active status within 1.5 to
2 y after having initially responded and multiple relapses were observed; after the second and third treatment 60% of
cysts relapsed within 2 y. We estimated that 2 y after treatment initiation 40% of cysts are still active or become active
again. The overall efficacy of benzimidazoles has been overstated in the past. There is an urgent need for a pragmatic
randomised controlled trial that compares standardized benzimidazole therapy on responsive cyst stages with the other
treatment modalities.
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Introduction
Cystic echinococcosis (CE, hydatid disease) is a parasitic disease
of worldwide prevalence. Hydatid cysts occur mainly in the liver
(70%) and the lung (20%). Clinical symptoms and signs depend on
their localisation, size, and number. Currently four treatment
modalities are in use: (1) surgery, (2) PAIR (puncture, aspiration,
injection of protoscolicidal agent, reaspiration), (3) chemotherapy
with albendazole (ABZ) or mebendazole (MBZ), and (4) watch and
wait for inactive, clinically silent cysts. The evidence supporting
any of the four treatment modalities, from carefully designed
clinical studies, is insufficient, and choosing treatment options for
patients remains controversial [1].
The use of benzimidazoles in CE treatment started in the 1970s
with MBZ. In the early 1980s ABZ was introduced and since then
has largely replaced mebendazole. The main advantages of ABZ
are claimed to be a lower dosage and better intestinal absorption.
In treatment centres MBZ and ABZ are given at the World Health
Organisation (WHO) recommended dosages of (MBZ, 40–50 mg/
kg/day; ABZ, 10–15 mg/kg/day) [2]. Variability exists in the
duration of treatment, which remains undefined. Duration of
treatment is determined according to the ultrasound-based
treatment response, resulting in repetitive treatment, which is part
of our analysis.
Chemotherapy for the treatment of CE was initially recom-
mended for inoperable patients and patients with multiple organ
disease [2,3]. Over the past decade several studies, mainly case
series, have been published suggesting that chemotherapy could be
an alternative to surgery in patients with uncomplicated cysts,
leading to an increased use of chemotherapy over the years [4].
After more than 30 y of benzimidazole use, the following crucial
question remains unanswered: what is the efficacy of benzimid-
azoles stratified by type and size of cysts, daily dose, and duration
of treatment?
This project started with a systematic review of the published
literature on the efficacy of treating CE with benzimidazoles. We
had to conclude, however, that we could not obtain a clear picture
of the long-term outcome of benzimidazole treatment because
inclusion criteria, treatment, outcome measures, and follow-up of
published studies varied widely with substantial overlap of cohorts
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[1], thus precluding a meta-analysis of published results. We
therefore initiated EchinoMEDREV, a collaborative effort of CE
specialists, to collect individual patient data from patients treated
with benzimidazoles.
The main objectives of this collaborative study were to describe
cyst outcome after initiation of benzimidazole treatment, with
outcome defined by cyst stage determined by ultrasound follow-
ing the WHO classification of 2001 [3], and to explore differences
in outcome by cyst stage and size at initiation of treatment by
using a common analytical strategy for all data across treatment
centres.
Methods
Literature Search
A systematic search of MEDLINE, EMBASE, CCTR, and
SIGLE was carried out from their inception until week 4 of 2004.
The search was performed by a research librarian using the
following search terms: echinococcosis, albendazole, mebendazole,
hydatid disease, cystic echinococcosis. We also searched reference
lists and asked researchers in the field for additional studies. No
language restriction was used. Abstracts were screened for
suitability by MS. The eligibility of studies was assessed
independently by two investigators (TJ and MS). We included
all types of study design with a minimum of 30 patients treated
either with ABZ or MBZ. Studies in which drug treatment was an
adjunct to surgery, PAIR, or a second drug were excluded.
Individual Patient and Cyst Data Collection
The studies identified in the literature search revealed that there
were large differences in baseline assessment of cyst stages,
interventions (dose and duration of chemotherapy), length of
follow-up, and outcome measures between published trials. These
differences precluded the possibility to perform a meta-analysis of
published results. Therefore we decided to collect individual
patient data from the identified centres and initiated the
EchinoMEDREV project.
Study centres that had conducted clinical studies on benzimid-
azole treatment of CE were contacted and asked to contribute
published and unpublished individual patient data of benzimid-
azole-treated CE patients. Data extraction forms were developed,
piloted, and revised. Data collection started in June 2005 and
ended in December 2007. Data were extracted from patient charts
at the individual treatment centres. Data collected were:
demographic data (age, sex); treatment data (MBZ, ABZ, dosage,
and duration of treatment, side effects, previous treatments);
imaging data (initial ultrasound staging and staging at follow-up
visits). The forms were sent to the coordinating centre at the
University Hospital in Heidelberg where data were electronically
entered into a database with EpiData, using data entry checks.
Accuracy in data entry was checked by double entry verification. A
final dataset was created after correcting detected data entry errors
and exported to Stata for statistical analysis. Patients with single or
multiple hydatid cysts were eligible. Cyst stage had to be recorded
at the beginning and at least once after completion of the initial
treatment episode. The minimum follow-up period was 1 y after
completion of initial treatment. Cyst activity had to be assessed by
ultrasonography and classified according to WHO (CL–CE5 or
active [A]/transitional [T]/inactive [I]), Gharbi, Perdomo, or
Caremani (Table 1).
Data Analysis
The analysis presented here includes only liver and peritoneal
cysts (70%–75% of all CE cysts in humans), which were assessed
by ultrasonography, and excluded lung cysts as they are not
usually assessed by ultrasonography.
Author Summary
Cystic echinococcosis (CE) is a parasitic infection of
worldwide occurrence transmitted to humans by dogs.
After infection cysts develop, mainly in the liver and lung.
Ultrasound-based staging of cysts into active, transitional,
and inactive has opened new venues for treatment and
follow-up. Currently four treatment modalities are in use:
(1) surgery, (2) percutaneous sterilization techniques, (3)
chemotherapy with benzimidazoles, and (4) watch and
wait for inactive cysts. However, evidence is insufficient for
these four modalities, and determining individual treat-
ment options for patients remains controversial. Medical
treatment with benzimidazoles started in the 1970s.
Important questions remain unanswered, however, such
as efficacy stratified by cyst type and the duration of
treatment. We therefore initiated EchinoMEDREV, a collab-
orative effort to collect individual patient data from
patients treated with benzimidazoles and to analyze cyst
outcome after initiation of benzimidazole therapy using a
common analytical strategy across treatment centres. We
found that the efficacy of benzimidazoles has been
overstated in the past. Additionally, natural cyst decay
has not been taken into account. Evidence from random-
ized controlled trials is urgently needed to determine the
true efficacy of benzimidazoles. Our analysis will help to
design benzimidazole trial arms on the basis of the
currently available best evidence.
Table 1. Ultrasound classification systems of CE cysts.
Gharbi et al. 1981 [32] Perdomo et al. 1995 [33] Caremani et al. 1997 [34] WHO 2001
G I, G III P 1
P 1a, 1b, 1c
P 2
C Ia
C Ib
C IIa, IIb
CL
CE1
CE2
A, active: unilocular simple cyst with uniform anechoic
content with or without visible cyst wall or
multivesicular, multiseptated cyst, presence of
daughter cysts, round or oval
G II, G IV P 3 C IIIa, IIIb;
C IV
CE3 T, transitional: unilocular cyst may contain daughter
cysts, anechoic content detachment of membrane,
form may be less rounded
G V P 4, 4a
P 5, 6
C Va, Vb
C VI,
VIIa,VII b
CE4
CE5
I, inactive: heterogenous, hypoechoic, or
hyperechoic degenerative content, no daughter
cysts, calcification of cyst
doi:10.1371/journal.pntd.0000524.t001
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Figure 1. Flow diagram of searches, study selection, and specialist centre identification.
doi:10.1371/journal.pntd.0000524.g001
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Table 2. Characteristics of study groups identified by the literature search where data were available.
Study Group Location Data Available Design n Patients Intervention ABZ/MBZ Follow-up (mo)
Italy/Rome Franchi et al. 1999 [14] PCS 448 MBZ or ABZ 12–168
De Rosa et al. 1996 (Italian, abstract only) [15] Not clear from
abstract
425 MBZ orABZ Not clear from abstract
Teggi et al. 1993 [16] PCS 337 MBZ or ABZ 6–103
Teggi et al. 1990 [17] PCS 50 ABZ 6–42
Bulgaria Vutova et al. 1999 [9] PCS 53 MBZ 36–84
Todorov et al. 1992 [10] PCS 51 MBZ or ABZ 12–48
Todorov et al. 1992 [11] PCS 79 MBZ or ABZ Mean 33
Todorov et al. 1990 [12] PCS 55 MBZ or ABZ Mean 28
Romania Radulescu et al. 1997 (Romanian) [19] PCS 67 ABZ 24
Italy/Palermo Sciarrino et al. 1991 [18] CS 50 ABZ Unclear
Greece Messaritakis et al. 1991 [13] PCS 39 MBZ Mean 63624
Turkey Go¨cmen et al. 1993 [20] PCS 56 MBZ 16–50
Abbreviations: CS, case series; PCS, prospective case series.
doi:10.1371/journal.pntd.0000524.t002
Table 3. Characteristics of study groups identified by the literature search where no data were available or no contact could be
established.
Study Group Location No Data Available/No Contact Established Design n Patients Intervention ABZ/MBZ Follow-up (mo)
Israel Nahmias et al. 1994 [21] CS 68 ABZ 36–84
China Chai JJ et al. 2004 [24] PCS 264 ABZ emulsion 24–48 y
Chai JJ et al. 2003 [23] CS 497 ABZ emulsion Unclear
Chai JJ et al. 2002 [22] PCS 212 ABZ emulsion 12–24
Wen H et al. 1994 [28] PCS 58 ABZ 36–84
Russia Shcherbakov AM et al. 1993 [25] CS 53 MBZ 6–72
Libya El-Mufti M et al. 1993 [26] CS 63 ABZ 24
Great Britain Horton RJ 1989 [27] CS 253 ABZ 24–62
Spain Gil-Grande LA et al. 1993 [6] RCT 55 ABZ 12
Iran Keshmiri M et al. 2001 [7] RCT 17 ABZ 48
Keshmiri M et al. 1999 [8] RCT 20 ABZ 15–48
Abbreviations: CS, case series; PCS, prospective case series; RCT, randomised controlled trial.
doi:10.1371/journal.pntd.0000524.t003
Table 4. Patient and treatment characteristics by centre: restricted to patients with liver and peritoneal cysts.
Centre
n Patients
(Total 612)
Age (y)
Mean6SD Sex
Previous
Treatment
(Medical or
Surgery)
n Treatment
Courses ABZ MBZ
ABZ
after
MBZ Drug Side Effects (Over All Treatment Episodes)
M F
Raised Liver
Enzymes Low WBC
Low
Platelets Hair Loss
ABZ MBZ ABZ MBZ ABZ MBZ ABZ MBZ
Rome 414 46.8614.9 149 265 243 2.461.3 290 15 109 106 2 7 0 9 0 27 1
Bulgaria 73 42.2618.1 33 40 39 160 51 22 — 4 0 0 0 0 0 5 0
Romania 59 40.4616.6 30 29 31 1.1160.37 59 — — 5 — 1 — 0 — 0 —
Palermo 33 51.9615.9 16 17 16 2.262.0 33 — — 3 — 0 — 1 — 1 —
Greece 23 7.362.2 11 12 0 1.060.2 — 23 — — 2 — 0 — 0 — 0
Turkey 10 763.3 3 7 2 160 7 3 — 0 0 0 0 0 0 0 0
Abbreviations: F, female; M, male; SD, standard deviation; WBC, white blood count.
doi:10.1371/journal.pntd.0000524.t004
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The cyst was used as the unit of analysis for a description of
achieved outcomes, and the presence of multiple cysts was not
taken into account. Data were analysed by intention-to-continue-
treatment, ignoring treatment changes (MBZ/ABZ), interruptions,
and subsequent treatment episodes.
We analysed several endpoints. First, initial treatment success
for a cyst was defined as transformation from an initially active or
transitional stage to an inactive stage or disappearance of the cyst
(see Table 1 for classification based on ultrasonography). For this
analysis time was measured from the start of first documented
treatment to the date the stage was assessed as inactive or as
disappeared or to the last documented assessment. Second, an
analysis was made of the time for a cyst to become active again
after the cysts had been staged as inactive; a necessary step, as
some cysts that had reached an inactive stage had subsequently
been staged as active again upon ultrasonography. For this analysis
time was measured from the first (or second, or third) date at
which a cyst was staged as inactive until the cyst was staged again
as active. For these separate endpoints we performed time-to-event
analyses using the Kaplan-Meier method and calculated the
cumulative incidence of the events by subtracting the Kaplan-
Meier survival estimate from one. Descriptive figures are presented
stratified by centre where appropriate.
Despite the fact that all previous studies on CE cyst
development had treated cysts as an independent unit of analysis
even if multiple cysts were present in the same patient, we
Table 5. Cyst characteristics: restricted to patients with liver and peritoneal cysts and to patients where total days of treatment
were available.
Centre
Total n Cysts
(A+T) (1,159)
n Cysts per
Patient
Mean6SD
Size of Cysts
Mean6SD (cm)
First Visit
Cyst Stages at
Presentation
Number of Follow-ups
per Cyst
Follow-up Years
per Cyst
Ultrasound
Classification Used
A T Ia
Rome 783 2.260.97 4.0961.99 550 233 124 6.3262.91 4.462.7 WHO
Bulgaria 176 2.762.03 3.9762.05 175 1 3 3.7361.46 2.362.5 WHO
Romania 96 1.6360.74 5.1163.81 90 6 0 6.4062.08 361.9 WHO
Palermo 56 1.7360.80 7.5164.91 50 6 1 9.9666.06 1066.3 Gharbi
Greece 32 1.3960.72 5.0761.83 32 0 0 3.9760.47 6.763.9 A/T/I
Turkey 16 1.660.84 4.4862.04 15 1 0 4.8161.38 1.561.2 A/T/I
aInactive (I) cysts are cysts in patients with multiple cysts. The inactive cysts have not been the indication for treatment and have not been included in the analysis.
Abbreviation: SD, standard deviation.
doi:10.1371/journal.pntd.0000524.t005
Figure 2. Length of follow-up per centre.
doi:10.1371/journal.pntd.0000524.g002
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addressed clustering of cysts within patients. The question of
heterogeneity by centre was also examined with data from several
treatment centres. When addressing clearly specified hypotheses—
such as the association of cyst size and time to inactivity or cyst
disappearance—Cox proportional hazards models were fitted and
a robust variance estimator was used [5] to account for the
clustering of cysts within patients. In addition indicator variables
were included for each centre. Two questions were investigated
using robust Cox proportional hazards model:(1) the association of
cyst CE stage at baseline with time to first inactivity or
disappearance, and (2) the association of cyst size (,6 cm versus
.6 cm) with time to inactivity or cyst disappearance. For the
second question the first year (day 0 to day 365) and the follow-up
time after year one (day 366 onwards) were analysed separately,
because descriptive cumulative incidence plots hinted at the
possibility that the cyst size mattered only after year one. Wald
test-based p-values were calculated to obtain a hypothesis test for a
whole group of indicator variables to be included in the robust
Cox proportional hazards model. p,0.05 was considered
statistically significant. For a general description of patients and
cysts included in this analysis, counts and mean and standard
deviation are provided where appropriate.
After observing and describing a multiphase phenomenon of
cyst response to treatment, we additionally performed a simulation
of the fate of 5,000 hypothetical cysts starting at treatment
initiation and moving across the different phases of becoming
inactive and relapsing to active. We made the simplifying
assumption that phase durations can be described by an
exponential distribution. We took the median and/or the 25th
percentile obtained from the cumulative incidence estimates for
the transitions from active to inactive and for the transitions from
inactive to active. We then derived the lambda parameter of the
exponential distribution via standard formulae: median, lamb-
da=median/ln(2); 25th percentile, lambda= p25/ln(1/0.75). We
further assumed that the duration of the next phase is independent
of the duration of the previous phase. For each simulated cyst we
assessed the current stage at year 1 to year 5 after treatment
initiation. All analyses were performed using Stata Version 10
(StataCorp).
Results
Out of 353 citations identified, 23 papers met the inclusion
criteria (Figure 1). Three publications were randomised controlled
trials [6–8], all other studies included were prospective or
retrospective case series [9–28]. 19 publications were in English,
one was written in Romanian [19], one in Chinese [23], one in
Russian [25], and one in Italian [15]. Tables 2 and 3 summarize
the characteristics of publications by the specialist centres
identified through the literature search.
All 14 specialist centres identified were contacted: no reply was
received from four centres [7,8,22–26]; one centre was unable to
Figure 3. First time a cyst was staged as CE4, CE5, or disappeared by stage at baseline (only centres using the WHO CE
classification).
doi:10.1371/journal.pntd.0000524.g003
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participate [6]; and nine centres agreed to participate. Of these
nine centres six provided data [9–20], the others were unable to
provide data [21,27,28]. In total we received data on 711 patients
with 1,308 cysts. Table 4 summarizes the characteristics of patients
with liver and peritoneal cysts. Table 5 shows cyst and follow-up
details. Figure 2 shows length of follow-up per centre.
The analysis presented here was restricted to patients with liver
and peritoneal cysts, because of the reliability of ultrasound
classification compared to other cyst locations. This restriction
resulted in 1,159 cysts in 612 patients for analysis. Approximately
68% of data was obtained from one centre (Table 4).
Figure 3 shows the treatment response of individual cyst stages.
Overall, 1–2 y after initiation of benzimidazole treatment 50%–
75% of cysts initially staged as active in the CE1 category were
staged as inactive or had disappeared compared to 30%–55% of
CE2 and CE3 cysts. In the robust Cox proportional hazards model,
CE3 stage cysts responded poorer than CE1 cysts from year one
onwards (p=0.043), but not up to year one (p=0.43), and a centre
effect was noted from year one onwards (p=0.033, Wald test).
We further analysed the rate of inactivation/disappearance with
regard to cyst size (Figure 4). Overall, 50%–60% of cysts,6 cm at
baseline responded to treatment after 1–2 y, compared to 25%–
50% of cysts .6 cm. In the robust Cox proportional hazards
model cysts ,6 cm responded better than larger cysts (p=0.006)
and a strong centre effect was noted (p,0.0001).
Figure 5 shows the cumulative incidence of reaching an inactive
stage or a disappearance of cysts for the first time by centres. Data
from Greece and Bulgaria show inactivation/disappearance rates
of cysts of 75%, increasing to around 90% within 2 y in Bulgaria.
In contrast data from Palermo show inactivation or disappearance
of cysts in approximately 20% of cases after 2 y. Data from Rome,
Romania, and Turkey are between Greece and Palermo.
Overall, cysts that reached an inactive stage for the first time
relapsed (returned into an A or T stage) in around 25% of cases
2 y after inactivation (Figure 6). Cysts that reached an inactive
stage for a second or third time showed relapse at a higher
proportion and at an earlier stage: 60% of cysts relapsed within 2 y
after the second or third inactivation.
Figure 7 shows the proportion of inactive/disappeared cysts
over time stratified by the first, second, and third time the cysts
started from A/T stages. The cumulative incidence curve after
first A/I reflects what has been observed after treatment initiation.
Cysts that were staged A/T for the second and third time were
staged as inactive or as disappeared in about 75% and 85% 1 y
later. These results were almost exclusively from the Rome centre.
In the simulation of hypothetical cysts, we estimated that 1 and
2 y after treatment initiation, 60% and 40% of cysts are still active
or become active again.
Discussion
In a collaborative effort, individual data from patients with CE
were pooled from six centres in five countries and outcomes of
liver and peritoneal cysts treated with benzimidazoles were
Figure 4. First time a cyst was staged as inactive or disappeared by size of cyst.
doi:10.1371/journal.pntd.0000524.g004
Benzimidazoles in Cystic Echinococcosis
www.plosntds.org 7 September 2009 | Volume 3 | Issue 9 | e524
described. We found a strong association between cyst activity and
response to treatment, with a better response in highly active CE1
cysts, and an association in treatment response depending on the
size of the cyst at the beginning of treatment, with cysts ,6 cm in
diameter responding better. Thus, our data suggest that small
highly active cysts show the best initial treatment response. Overall
25% of cysts reverted to active status within 1.5 to 2 y after having
initially responded, and multiple relapses were observed. We
estimated that 2 y after treatment initiation 40% of cysts are still
active or become active again. Our results are biologically
plausible because early in the disease host response resulting in
an increasing thickness of the pericyst and consolidation of cyst
content has not yet reached a degree that prevents the drug to
reach its target [29]. Additionally, it is important to note that
natural decay is a component of the observed rate of inactivation.
Available data suggest that this decay may be as high as 13.6%
within 18 mo [29], and up to 20.6% within 44 mo [30]. This
finding clearly leads to an overestimation of response to
benzimidazole treatment as calculated from longitudinal data,
which increase with the length of observation.
There are several limitations to this study. The published data
collected from participating specialist centres are from case series.
Results from case series are considered low level evidence in
determining the efficacy of treatment options. In several analyses we
found heterogeneity by centre. For example, the cumulative
incidence curves for reaching an inactive cyst stage for the first
time or the disappearance of a cyst after initial treatment showed
large intercentre variability. Greek and Bulgarian data show a very
rapid response, whereas data from Palermo show a very sluggish
response to treatment. Time to first inactivation of cysts in the other
centres looks quite similar. Rapid response to treatment in Greece
and Bulgaria, however, remains unexplained. The particularly slow
response to treatment shown in the dataset from Palermo could be
due to the larger mean size of cysts at presentation, the difficulty of
translating the Caremani classification into the WHO ultrasound
classification (Table 1), and the well-known fact that inter-rater
agreement between experts on classification of certain cyst stages is
low, in particular for cysts containing daughter cysts—stage CE2
and stage CE3b according to WHO. Depending on the amount of
consolidated matrix, cysts are either classified CE2 (daughter cysts
with no matrix) or CE3b (daughter cysts with matrix).This
distinction is important since the former is regarded active, the
latter transitional [31]. Interobserver discrepancies occurred in the
description of transitions from the inactive stages CE4 and CE5 to
the active stages CE1 or CE2; some observers described these
transitions and regard them as possible, whereas others do not.
However, the number of misclassified cysts is not quantifiable in a
retrospective dataset. It is very difficult, if not impossible, to consider
all types and directions of biases when attempting to estimate the
response of CE cysts to benzimidazoles from the available data. A
very strong bias is certainly introduced by differing observation
times with considerable impact on inactivation due to spontaneous
involution. A final problem concerns data that we were unable to
obtain (Table 2). Two centres that initially offered to deliver large
datasets were eventually unable to do so. Two-thirds of our data
have been provided by Rome, consequently the results are
predominantly from one centre.
Despite these limitations, to our knowledge, this study represents
the largest CE dataset ever collected and analyzed in a uniform
approach; further it is likely the only dataset obtained from the
main international specialist groups. The recommendations on
benzimidazole treatment of CE are currently based on the
published results from these centres. Through the collection of
individual patient data and the pooled analysis of these data we
have managed to overcome some of the existing limitations
present in the published literature.
Figure 5. First time a cyst was staged as inactive or disappeared by centre.
doi:10.1371/journal.pntd.0000524.g005
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Figure 6. Time an active or transitional stage was reached stratified by the number of times an inactive stage had been reached
previously (only centres that recorded recurrences are included).
doi:10.1371/journal.pntd.0000524.g006
Figure 7. Time an inactive or disappeared stage was reached for the next time, stratified by the number of times an active or
transitional stage had been reached previously.
doi:10.1371/journal.pntd.0000524.g007
Benzimidazoles in Cystic Echinococcosis
www.plosntds.org 9 September 2009 | Volume 3 | Issue 9 | e524
Does our study provide sufficient evidence to influence decisions
for the treatment of CE? We think that our results are strong
enough to cast doubts on overoptimistic expectations of the overall
efficacy of benzimidazoles. When looking into substrata of the cyst
population small CE1 cysts (diameter ,6 cm) are a promising
target for benzimidazole therapy, whereas stage CE2 and CE3
cysts respond poorly. The available evidence from this and other
studies does not yet allow us, however, to formulate solid evidence-
based drug treatment recommendations across all cyst stages, sizes,
and locations. Our results highlight the urgent need to compare in
a pragmatic randomised controlled trial the effect of standardized
benzimidazole dose regimens on the individual active cyst stages
(CE1, CE2, CE3a, and CE3b) substratified by cyst size. Such a
trial would investigate as a primary outcome the proportion of
cysts that become inactive (cyst stages CE4 and CE5) after
treatment, and as a secondary outcome the yearly relapse rates up
to 5 y after completion of treatment. The clarification of the
efficacy of benzimidazoles in CE treatment is of paramount
importance since benzimidazoles are the only drugs currently
available to treat this neglected disease. Surgery as an alternative
to benzimidazoles carries a significantly higher risk of adverse
events, in particular intra- and postoperative morbidity and
mortality and disseminated disease due to intraoperative spillage of
viable hydatid material. Percutaneous fine needle techniques such
as PAIR are only applicable to cyst stages CE1 and possibly CE3a,
but not to CE2 and CE3b, which makes it necessary to explore
large bore catheter techniques if albendazole turns out to be less
effective in these cyst stages as suggested by our analysis.
Supporting Information
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Found at: doi:10.1371/journal.pntd.0000524.s001 (0.17 MB PDF)
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